Sinphar Pharmaceutical Co. Ltd. · TWSE:1734
Sinphar Pharmaceutical — 2024 Sinphar Pharmaceutical Investor Conference
35 slides from Sinphar Pharmaceutical's conference presentation, Dec 19, 2024
Slide 1: Sinphar Pharmaceutical 2024 Investor Conference
SINPHAR PHARMACEUTICAL CO., LTD. 2024 Investor Conference Chairman Chih Wen Lee General Manager: Yu Liang Pei Chief Financial Officer: Chih Hsiao Chen December 19, 2024 1
Slide 2: Disclaimer
Disclaimer 本簡報是建立於本公司從各項來源所取得之資訊。有些 訊可能受未來不確定性因素影響，致使與原先本公司對 於未來前景的說明迥異。未來若有變更或調整時，請以 公開資訊觀測站公告資訊為依據。 所涉產業為法規高度規範與高度專業領域，提醒投資人 須審慎投資。 This presentation is based on the information obtained from various sources which the Company believes to be reliable. But at some point in the future, there ar
Slide 3: Contents
Contents 1. Outlook 2. Operations Development 3. Financial Reports 4. Sustainable Development 3
Slide 4: From Taiwan to the World
From Taiwan to the World 2000 Sinphar TPEx-listed 2002 Sinphar TWSE-listed 2014 SynCoreBio TPEx-listed 1977 2002 2012 Established Sinphar Invested in Sinphar TianLi & Merged ZuniMed Ilan, Taiwan He-Tian Tianli Biotech Generic drugs, functional food, Hangzhou (CN), Xinjiang(CN) Nantou, Taiwan cosmeti
Slide 5: Major Developments
Major Developments Diverse Development of Generic Drugs Value-added New Drugs R&D Comprehensive Plans for Natural Plant Extracts 5
Slide 6: Integration of Resources
Integration of Resources Sinphar & SynCore • Joint R & D • Improvement in Oncology manufacturing (Example: freeze-drying Dosages process) Sinphar & TianLi Natural Medical • Mutual benefit in Herbal Devices R&D achievement Extraction • Strategic cooperation for Sinphar & ZuniMed patented products ISO
Slide 7: Integration
Stride Ahead According to TFDA as of 12/1 and DCB data: Integration 1. API manufacturer:29 Supplier 2. Western medicine Exporting to over 10 manufacturer:144 countries/regions and increasing. 3. Pharmaceutical/medicinal related companies: over 100 4. Medical device companies: over 10,000 Internation
Slide 8: Talent Management
Talent Management 1. Hard assets: Bronze prize winning TTQS approved vocational training center 2. Intangible assets: utilize Talent Management System (TMS) to track and learning and professional development. 3. Since 2024, TMS recorded an average monthly use of 170.8 employees, monthly average log-
Slide 9: Comprehensive health promotion
Comprehensive health promotion Drugs Recovery New Product Released in 2024: 1 New Product Released in 2025: 2 Staying Healthy Youthfulness Functional Supplements Medical Cosmetology Products New Product Released in 2024: 3 New Product Released in 2024: 4 New Product Released in 2025: 4 New Product R
Slide 10: Comprehensive Product Line for All Ages
Comprehensive Product Line for All Ages Dermatology Ophthalmology Pediatrics Oncology Otolaryngology Orthopedics Obstetrics & General Surgery Plastic Surgery Gynecology Metabolism Dental Gastroenterology Urology General Medicine Psychiatry 10
Slide 11: Health Around the Corner
TP Sesaakan aaZRaA RE Life * Health TaCHiOlSey)
Slide 12: Post Pandemic Care
©7538 Bo ee iat roe Post Pandemic Care By COV Ot REE TTRLLHIRONEEN lan L iw a x #8. BE 25 BR BE AG i GS 7S / ABRIL) — onmaana 4 mde Bie HESE MATA i * 4 . Sie a HELE CHR A pa aus. G8 SRRBAERE ee Aameae Bie HLPNESEE AEE 2 ORME SOM RD HES aw ip > FH Life + Health + Technology
Slide 13: International Award Winning Product
International Award Winning Product 13
Slide 14: Potent Plus Soft Capsules
| “See eee SINPHAR GROUP Support Heart Health nix eS Anti-Fatigue plat RITES WS BAMA 75 pray Fie 2) 3 Exclusive Anti-Fatigue Ingredients With Patents Echinacoside QH D-Ribose Potent Plus Soft Capsules (GAIA SE RB 1 FSB HE AES Bi LE 8 TBE) a ELI Baa 7 h ih nm Levels ts High © p 5 paten™ > AS 8) Y) BE
Slide 15: 107 human trials confirm immune support
經107例人體試驗 證實有感提升保護 *文獻發表中 經國際學術發表文獻證實 具調節免疫、緩解過敏體質雙重作用
Slide 16: Health Foods for Aging Society
Health Foods for Aging Society 三高全照護健康食品系列
Slide 17: Sinphar Health Park – Sharing Knowledge with the Public
Sinphar Health Park – Sharing Knowledge with the Public 1. Since the opening of the Park, over 80,000 people have visited to understand the manufacturing process of pharmaceuticals and food products. An expansion plan is underway to accommodate the expected over 30,000 visitors for 2025 2. Located n
Slide 18: Production Digitalization
Production Digitalization Production Plan Scheduling Shipping Create Work BI Cockpit Warehouse MRP Order PO Warehouse Receiving ISO/IEC 27001 IQC ISMS QA Warehouse FQC Warehouse Weighing Packaging Picking MM WIP Warehouse MP WIP Warehouse IPQC Cockpit ERP LIMS Production Data APS MES PLC & Equipment
Slide 19: International Markets
International Markets Japan • Product G, launched in 2020, steady Philippines growth • Product L, applied in 2022, expect to Thailand launch in 2024 • Product T, applied in 2024, expect to • Product G, obtained license in 2023 launch in 2026 Vietnam • Product G, obtained license in 2023 • Product G,
Slide 20: Sustainability
Sustainability Energy Saving Carbon Energy Intensity* Reduction Continues to Decrease Emission Intensity* (2023 vs 2021) Continues to Decrease (2023 vs 2021) 17.3% (Purchased electricity + liquefied 17.0% petroleum gas + diesel = Emission from Scope 1 + Scope 2 = gigajoules/revenue in millions NTD)
Slide 21: Growth
Growth Therapeutic Drugs • New listing expected in 2025: 1 (Mild eczema and seborrheic dermatitis) • Co-develop and manufacture with Japanese pharmaceutical companies and expand ASEAN market • Agent to Japanese products for domestic market • API in-depth development plan (Sulfamethoxazole and Mesulp
Slide 22: Management Philosophy
Management Philosophy 580,000 575,000 蘭陽媽祖文化節 贊助杏輝宜蘭馬拉松 570,000 565,000 560,000 555,000 550,000 贊助失智症照護協會 與縣政府共同推廣搶孤 111年前三季 112年前三季 113年前三季 (*內含員工薪資、勞健保、退休金及其他用人費用) 捐贈宜蘭縣政府防疫物資 112年頭城、台南搶孤冠軍 112年杏輝宜蘭馬拉松 連續九年杏輝生技營 優良食品製造業者楷模 22
Slide 23: Pipeline
Pipeline SynCoreZ PRE- INNOVATIVE DRUG CLINICAL PHASE | PHASE II PHASE Ill NDA MARKETED SB01 Head & Neck Cancer > RRALARR RAI sssosatn carn $02 Solid Tumor = : Oncology A EndoTAG -1 _ Pancreatic Cancer (PC) rr C**" ina: <a0s hina EndoTAG -1 > . Taiwan Triple Negative Breast Cancer (TNBC) : Dermatolo
Slide 24: Sinphar Group's New Drug Catalog
Refer to Annual Report from Sinphar and Sinphar Group's New Drug Catalog SynCore for more details Memoregain® SB05 PC SB03 Veregen TLCT Plus Pancreatic Cancer Vascular dementia EGW Second Line Treatment:Clinical trial Phase Ⅲ Launched in 20 Obtained license First Line Treatment: NMPA approved; Phase
Slide 25: Natural resources: Memoregain, TLCT Plus, Lipucan
天然資源（原料/提取物） Memoregain® Lipucan® Protygold ® KAZINAKE ® TLCT Plus 天力速康® 杏补宜 ® 杏补宜 ® 天力再生® 茯苓三萜菁萃物 核桃肽 初榨核桃油 (Poria cocos (Walnut oligopeptide) (Walnut Oil) 管花肉蓯蓉提取物 triterpenoids) (Cistanche tubulosa extract) Organic certification EU Ecocert、USDA Organic、China Organic Food Certification Center 25
Slide 26: RD research achievements
RD research achievements Walnut oil won the ITQI and Monde Selection awards in 2023 Walnut oligopeptide won 4 gold and 1 silver international patent invention awards in 2022 Walnut oligopeptide obtains Nutritional Intelligence_ New Plant Power Award in 2023 SCI papers The ingredient has been sold to
Slide 27: Differentiated Marketing
Differentiated Marketing • Major markets in Taiwan and China as food raw material; begin to export in 2024 now sold to 14 countries around Market the world, with focus on northeast Asian and ASEAN countreis • Looking for new markets post COVID-19 pandemic • Provide specialized customer support with
Slide 28: Revenue Overview for the Same Period in Recent Years
Revenue Overview for the Unit：NTD in thousands Same Period in Recent Years 2,500,000 40.0% 2,296,239 2,214,367 2,094,144 2,000,000 39.0% 39.0% 38.7% 1,500,000 38.0% 1,000,000 37.0% 500,000 36.5% 0 36.0% 111年前三季 112年前三季 113年前三季 療效用藥 功能性食品 其他 合計 毛利率 1. As of November 2024, cumulative sales revenue is
Slide 29: Cash Flow
Unit: NTD in Thousands Cash Flow Sinphar Group Sinphar Group Sinphar Group Q1~Q3 2024 2023 Q1~Q3 2023 Net Cash generated by 405,341 296,370 155,564 operating activities Net Cash used in investing -300,957 -334,563 -250,019 activities Acquisition of property, plant and equipment -137,646 -198,725 -13
Slide 30: Ratio
Unit: NTD in Thousands Ratio Sinphar Group Sinphar Group Q1~Q3 2024 Q1~Q3 2023 Debt Ratio (%) 44.6 47.0 Current Ratio (%) 227.0 207.7 Accounts Receivable Turnover 5.12 4.43 Accounts Payable Turnover 7.52 6.23 Inventory Turnover 2.31 2.41 Sinphar Group SynCore Q3 2024 Q3 2024 Cash and cash equivalent
Slide 31: Sustainability
Sustainability Risk Corporate Honesty Management Management Global Talent recruit and Customer warming maintenance health Energy Occupational Supply chain management safety and health management Social Innovation and Environmental Responsibility R&D 31
Slide 32: Corporate Social Responsibility
Corporate Social Responsibility 1. Host health forum, biotechnology camp. Create a platform to facilitate and cultivate the interaction of medical, academic, and biotechnology professionals 2. Continue to be a sponsor for Breast Cancer Foundation, Spinal Cord Injury Foundation, The Diabetes Associat
Slide 33: Corporate Social Responsibility
Corporate Social Responsibility Supports Education and Sports 1. Donate NTD 5 million over 5 years to Kaohsiung Medical University for students in need of financial assistance 2. Sinphar Group and Yilan County Government will jointly organize annual “Sinphar Yilan Marathon” for 3 years with a sponso
Slide 34: PH BAR
PH BAR tC: ROR —— MIRRABRE: REX SRI RAVRE 8 7 fle sen ee HES SRESREHEHRD PSOE a EY HEARS M3 HE12)28 (rn) HIE im a Riie ih nat a dad b m+ 2 # > HH Life * Health * Technology Ge
Slide 35: Sinphar Group
“SR RRSe SINPHAR GROUP m+ #2 B > #H Life » Health * Technology SS —~——
Sinphar Pharmaceutical — 2024 Sinphar Pharmaceutical Investor Conference on 6ix